Search results for " market" in Articles / App Notes
Article
Regulatory Challenges in the QbD Paradigm
Under the QbD paradigm, the success or failure of a marketed pharmaceutical product is assessed to incorporate lessons learned into future reviews of drug applications.
An integrated model of re…
Article
Moving PAT from Concept to Reality
Overall, therefore, PAT contributes to acceleration of process development timelines for reduced time to market, concludes Carbonell.
PAT should also ultimately make real-time product release poss…
Article
The Challenge of Disruptive Technologies in Bioprocessing
“When we look at the biologics market dynamics for treatment of diseases, certainly the increasing demand for biopharmaceuticals and the growing R&D expenditure in biopharma companies are factors driv…
Article
Biopharma in 2016: Higher Quality Drugs, Less Expensive Manufacturing
The global biopharmaceuticals market was valued at $162 billion in 2014 and pre¬dicted by Persistence Market Research to grow at a compound annual growth rate of 9.4% from 2014 to 2020 to reach $278 b…
Article
Improving Process-Scale Chromatography
She points to several new types of affinity chromatography resins introduced to the market in recent years that target recombinant plasma proteins, gene therapy applications, and different types of an…
Article
Biopharma in 2015: A Year for Approvals and Innovations
The EU was the first geographic market to develop the process of authorization of biosimilars, setting an example for many other developing markets to follow suit. As of 2015, the EU approved 19 biosi…
Article
Biosimilars Will Bring Significant Litigation and Patent Challenges
Pre-litigation steps for biologics has been set out by the BPCIA, wherein a biosimilar sponsor may challenge an unexpired patent in an attempt to enter the market before the originator patent expires.…
Article
Continuous Manufacturing: A Changing Processing Paradigm
While only a few approved biologic products in the market—less than 10%, according to estimates by Eric Langer, managing partner, BioPlan Associates—are manufactured through perfusion or continuous do…
Article
Setting Standards for Biotech Therapeutics in India
The biopharmaceuticals market has witnessed the fastest growth in the 2013 financial year as compared to other biotech markets (e.g., Bio-Agri, Bio-Services, and Bio-Informatics).
Growth in this s…
Article
Report: Branded Biopharms Most Exposed to Biosimilar Competition
Many of the largest branded biotech products in the US market today are now in biosimilar development by at least one company, Levesque says, and the pipeline is expanding. Blockbuster biotechs facing…